Pharmacokinetic Modelling of the Plasma Protein Binding of Mycophenolic Acid in Renal Transplant Recipients

被引:34
|
作者
van Hest, Reinier M. [1 ]
van Gelder, Teun [1 ,2 ]
Vulto, Arnold G. [1 ]
Shaw, Leslie M. [3 ]
Mathot, Ron A. A. [1 ]
机构
[1] Erasmus MC, Dept Hosp Pharm, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus MC, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands
[3] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
关键词
PHARMACODYNAMIC RELATIONSHIP; CLINICAL PHARMACOKINETICS; KIDNEY-TRANSPLANTATION; FREE FRACTION; MOFETIL; GLUCURONIDE; CYCLOSPORINE; VARIABILITY; TACROLIMUS; CLEARANCE;
D O I
10.2165/11312600-000000000-00000
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objectives: Renal function and the plasma albumin concentration have been shown to correlate with clearance of total mycophenolic acid (MPA). The hypothesis for the underlying mechanism is that low plasma albumin concentrations and accumulation of the glucuronide metabolite of MPA (MPAG) decrease the binding of MPA to albumin. The subsequent increase in the unbound fraction (f(u)) of MPA (MPA(u)) produces an increase in total MPA (MPA(t)) clearance. This study aimed to develop an empirical population pharmacokinetic model to describe the relationships between renal function and albumin concentration and MPAG, MPA(u) and MPA(t), in order to provide insight into the mechanism by which renal function and plasma albumin affect the disposition of MPA. Methods: 774 MPA(t), 479 MPA(u) and 772 total MPAG (MPAG(t)) plasma concentrations were available from 88 renal transplant recipients on days 11 and 140 after transplantation. Data were analysed using non-linear mixed-effects modelling. Results: Time profiles of MPA(u) and MPAG(t) concentrations were adequately described by two 2-compartment pharmacokinetic models with a link between the central compartments, representing the glucuronidation of MPA(u) to form MPAG. MPA(t) concentrations were modelled using: [MPA(t)]=[MPA(u)] + [MPA(u)].theta(pb), with [MPA(u)].theta(pb) representing the bound MPA concentration, where [MPA(t)], [MPA(u)] and Orb represent MPA(t) concentration, MPA(u) concentration and a factor that correlates to the total number of protein binding places, respectively. According to this equation, f(u) = [MPA(u)]/[MPA(t)] = 1/(1 + theta(pb)).theta(pb), and therefore [MPA(t)], was significantly and independently correlated with creatinine clearance (CL(CR)), the plasma albumin concentration and the MPAG(t) concentration (all p < 0.001). A reduction in CL(CR) from 60 to 25 mL/min correlated with an increase in f(u) from 2.7% to 3.5%, accumulation of MPAG(t) concentrations from 50 to 150 mg/L correlated with an increase in f(u) from 2.8% to 3.7%, and a decrease in plasma albumin concentration from 40 to 30 g/L correlated with an increase in f(u) from 2.6% to 3.5%. No significant correlations were detected between MPA(u) clearance and the plasma albumin concentration or CL(CR). Conclusion: The model shows that low CL(CR), low Plasma albumin concentrations and high MPAG concentrations decrease MPA(t) exposure by affecting MPA binding to albumin.
引用
收藏
页码:463 / 476
页数:14
相关论文
共 50 条
  • [21] Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: A population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients
    van Hest, Reinier M.
    Mathot, Ron A. A.
    Pescovitz, Mark D.
    Gordon, Robert
    Mamelok, Richard D.
    van Gelder, Teun
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (03): : 871 - 880
  • [22] A population pharmacokinetic model for mycophenolic acid and metabolites in kidney transplant recipients.
    Akhlaghi, Fatemeh
    Sam, Wei J.
    Rosenbaum, Sara E.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 448 - 448
  • [23] Adverse effects of mycophenolic acid in renal transplant recipients: gender differences
    Ana Spasić
    Aleksandra Catić-Đorđević
    Radmila Veličković-Radovanović
    Nikola Stefanović
    Predrag Džodić
    Tatjana Cvetković
    [J]. International Journal of Clinical Pharmacy, 2019, 41 : 776 - 784
  • [24] Population pharmacokinetics of mycophenolic acid and its determinants in renal transplant recipients
    van Hest, RM
    van Gelder, T
    Vulto, AG
    Mathôt, RAA
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (01) : 106 - 107
  • [25] Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia
    Atcheson, BA
    Taylor, PJ
    Kirkpatrick, CMJ
    Duffull, SB
    Mudge, DW
    Pillans, PI
    Johnson, DW
    Tett, SE
    [J]. THERAPEUTIC DRUG MONITORING, 2004, 26 (03) : 284 - 286
  • [26] Time-dependent clearance of mycophenolic acid in renal transplant recipients
    van Hest, Reinier M.
    van Gelder, Teun
    Bouw, Rene
    Goggin, Timothy
    Gordon, Robert
    Mamelok, Richard D.
    Mathot, Ron A.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (06) : 741 - 752
  • [27] Adverse effects of mycophenolic acid in renal transplant recipients: gender differences
    Spasic, Ana
    Catic-Dordevic, Aleksandra
    Velickovic-Radovanovic, Radmila
    Stefanovic, Nikola
    Dzodic, Predrag
    Cvetkovic, Tatjana
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (03) : 776 - 784
  • [28] Significant Effects of Renal Function on Mycophenolic Acid Total Clearance in Pediatric Kidney Transplant Recipients with Population Pharmacokinetic Modeling
    Yan Rong
    Jenny Wichart
    Lorraine Hamiwka
    Tony K. L. Kiang
    [J]. Clinical Pharmacokinetics, 2023, 62 : 1289 - 1303
  • [29] The effect of renal insufficiency on mycophenolic acid protein binding
    Kaplan, B
    Meier-Kriesche, HU
    Friedman, G
    Mulgaonkar, S
    Gruber, S
    Korecka, M
    Brayman, KL
    Shaw, LM
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (07): : 715 - 720
  • [30] Significant Effects of Renal Function on Mycophenolic Acid Total Clearance in Pediatric Kidney Transplant Recipients with Population Pharmacokinetic Modeling
    Rong, Yan
    Wichart, Jenny
    Hamiwka, Lorraine
    Kiang, Tony K. L.
    [J]. CLINICAL PHARMACOKINETICS, 2023, 62 (09) : 1289 - 1303